GGrantIndex
Sort

141,003 grants matching cytokine

A Multi-Center Group to Study Acute Liver Failure

$1,000,000
William M Lee · Ut Southwestern Medical Center · U01 · FY2019 · DK

Therapy and Prophylaxis for Genital Tract Infection

$1,000,000
Dominick Auci · Therapyx, Inc. · SB1 · FY2023 · AI

Preclinical development of an immunomodulatory agent capable of mitigating SARS-CoV-2 virus related hypercytokinemia

$1,000,000
Jodi K Craigo · Cytoagents, Inc. · R44 · FY2021 · AI

Therapy and Prophylaxis for Genital Tract Infection

$1,000,000
Dominick Auci · Therapyx, Inc. · R44 · FY2021 · AI

Advanced generation infection-proof anti-HIV CAR-T with YY1 RNAi to block T cell exhaustion in NHP model

$1,000,000
Richard P Junghans · It Bio, Llc · R44 · FY2023 · AI

GASTROINTESTINAL HORMONE RESEARCH CORE CENTER

$1,000,000
University Of Michigan At Ann Arbor · P30 · FY2005 · DK

Enabling Technology to Prepare Ultrapure Dialysate in Dialysis Clinics

$999,999
Mohamed E Labib · Novaflux Technologies, Inc. · R44 · FY2012 · DK

Chronic Kidney Disease in Children (CKiD)

$999,999
Bradley Alan Warady · Children'S Mercy Hosp (Kansas City, Mo) · U01 · FY2008 · DK

SIRPant Technology for anti-Cancer Immunity

$999,999
Nathanael McCurley · Bobcatbio, Inc. · R42 · FY2024 · CA

KL4 Surfactant to Mitigate Radiation-Induced Lung Injury

$999,999
Robert Segal · Discovery Laboratories, Inc. · R44 · FY2014 · AI

Soluble high-affinity T cell receptors prevent MRSA lethality

$999,999
Adam Chervin · Immuven, Inc. · R44 · FY2012 · AI

Enabling Technology to Prepare Ultrapure Dialysate in Dialysis Clinics

$999,999
Mohamed E Labib · Novaflux Technologies, Inc. · R44 · FY2013 · DK

Early clinical development of a novel IL-7R antibody for treating children with relapsed T-cell leukemia

$999,997
Atul Varadhachary · Fannin Partners, Llc · R44 · FY2022 · CA

Development of GIFT4: a B cell focused immunotherapy for cancer

$999,997
Paul Guyre · Celdara Medical, Llc · R44 · FY2018 · CA

Early clinical development of a novel IL-7R antibody for treating children with relapsed T-cell leukemia

$999,997
Atul Varadhachary · Fannin Partners, Llc · R44 · FY2025 · CA

Preclinical evaluation of a novel small molecule STAT inhibitor

$999,993
Robert Sons · Fannin Partners, Llc · R44 · FY2018 · AI

CMC of Peptide Formulation for the Treatment of ARDS

$999,993
Gerardo M. Castillo · Pharmain Corporation · R44 · FY2022 · HL

Data Coordinating Center for PKD Treatment Network

$999,991
Washington University · U01 · FY2003 · DK

Targeting lipid rafts for treatment of asthma

$999,991
Yakov Kogan · Raft Pharmaceuticals, Llc · R44 · FY2023 · AI

A Novel Bispecific Antibody for the Treatment of Idiopathic Pulmonary Fibrosis

$999,989
Neil A Fanger · Virtici, Llc · R44 · FY2025 · HL

Small Molecule Antagonists of PF4 for the Treatment and Prevention of HIT

$999,965
Jay Edward Wrobel · Fox Chase Chemical Diversity Center, Inc · R44 · FY2021 · HL

A Novel Glycosaminoglycan-Based Therapeutic for Chronic Rhinosinusitis

$999,953
Abigail Pulsipher · Glycomira, Llc · R44 · FY2021 · AI

Small Molecule Antagonists of PF4 for the Treatment and Prevention of HIT

$999,945
Jay Edward Wrobel · Fox Chase Chemical Diversity Center, Inc · R44 · FY2019 · HL

Factor XII Inhibitor for Surface Initiated Thrombosis

$999,930
Erik Ian Tucker · Aronora, Inc. · R44 · FY2020 · HL

Novel Strategies to Clear Bacteria from the CF Lung

$999,919
Saira Ahmad · Eldec Pharmaceuticals, Inc. · R44 · FY2022 · HL